Skip to content

OABIW

OmniAb, Inc.

NASDAQ · Healthcare · Biotechnology · US

$0.41
−2.38%
Ask drillr

Year over year

Reported trailing growth

Revenue
+66.9%
EBITDA
+60.9%
EBIT
+31.6%
EPS
+40.0%
Free cash flow
+43.4%
Operating cash flow
+43.8%

Forward estimates

Based on analyst estimates

Revenue
-29.9%
EBITDA
—
EPS
-19.8%

Three-year CAGR

Revenue
-31.9%
EBITDA
+6.9%
EBIT
+4.0%
Net income
-4.4%
EPS
+6.6%
Free cash flow
+10.9%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026